Thymosin Alpha-1

Overview

Thymosin Alpha-1 (Tα1, sold internationally under the brand name Zadaxin as thymalfasin) is a synthetic 28-amino-acid peptide originally identified as an active fraction of thymic tissue extract by Allan Goldstein and colleagues in the 1970s. It is N-acetylated at its N-terminus and was the first thymic peptide to be fully characterised, synthesised and licensed for clinical use.

Tα1 occupies an unusual place in this site's coverage. Unlike most peptides discussed here, it is a licensed medicine in more than 30 countries — predominantly for adjunct treatment of chronic hepatitis B and chronic hepatitis C, and as a vaccine-response adjuvant in immunocompromised populations. It has been studied in human use for over three decades and has an extensive published safety dataset.

Tα1 appears on this site because of its emerging position in longevity research: immunosenescence — the age-related decline of adaptive immunity, particularly naive T-cell output — is one of the more clearly characterised hallmarks of ageing, and Tα1 is among the few clinical-stage agents with documented activity on T-cell maturation pathways. Interest in repositioning Tα1 from infectious-disease adjunct to immunosenescence intervention has grown over the past decade.

Mechanism of action

Tα1 acts through Toll-like receptor (TLR)-mediated signalling, primarily TLR-2 and TLR-9 on dendritic cells and other antigen-presenting cells. Engagement of these receptors triggers MyD88-dependent signalling, NF-κB and IRF-7 activation, and production of type-I interferon (IFN-α, IFN-β) and pro-inflammatory cytokines including IL-12.

Downstream, Tα1 supports maturation and differentiation of naive T cells in the thymus and peripheral immune tissue. It increases CD4⁺ T-cell counts in immunocompromised populations, restores Th1 cytokine balance in chronic viral infection, and improves antigen-presentation efficiency through dendritic-cell maturation. Effects on natural killer (NK) cell cytotoxicity have also been reported.

The principal longevity-relevant axis is its activity on naive T-cell output and immune-cell maturation. In ageing, thymic involution and reduced peripheral T-cell receptor diversity produce vulnerability to novel pathogens and reduced vaccine-response efficiency. Tα1 has been investigated as a potential intervention against this decline, with positive pilot data on influenza vaccine response in older adults.

Tα1 does not directly suppress immune activation in autoimmune contexts and is generally considered an immune-restorative rather than immunostimulatory agent — it tends to restore balance in dysregulated immune states rather than producing broad activation.

Research history

Tα1 was characterised by Allan Goldstein's group at George Washington University in the 1970s, isolated initially from bovine thymus extract and subsequently produced by chemical synthesis. The compound entered clinical development under SciClone Pharmaceuticals through the 1990s, achieving licensing in Italy and other countries for chronic hepatitis B and chronic hepatitis C.

Clinical research expanded through the 2000s to include adjuvant use with influenza vaccination in elderly populations (Carraro et al. demonstrated improved seroconversion rates), sepsis (with mixed results in phase III), and supportive care in cancer immunotherapy. During the 2020 pandemic period Tα1 was investigated as adjunct therapy in severe COVID-19 with some early observational data suggesting improvement in lymphopenia.

The repositioning toward immunosenescence and healthspan applications has been more recent. Published work on age-related thymic involution and on improving vaccine response in the elderly has provided a coherent rationale for further research in healthy ageing populations.

Summarised studies